Why this document matters
A snapshot of oxygen therapeutics at a pivotal moment.
The report captures Biopure at the point where an oxygen-carrier platform had moved beyond laboratory development into regulatory approval, advanced human clinical testing, veterinary commercialization and industrial manufacturing. It is useful today not as current clinical guidance, but as a primary historical record of how the field defined the problem: oxygen delivery as a therapeutic function that can become constrained when donor blood is unavailable, incompatible, difficult to store or too slow to reach the patient.
South Africa · HemopureThe report records the April 2001 Medicines Control Council approval of Hemopure for acutely anemic adult surgery patients, with the aim of eliminating, reducing or delaying allogeneic red-cell transfusion.
United States · Phase III developmentBiopure reported that primary endpoints were met in a U.S. Phase III orthopedic surgery trial and described preparations for an electronic BLA submission.
Human clinical programThe report states that more than 1,300 patients had been enrolled and more than 800 had received Hemopure across 22 clinical trials in the United States, Europe, South Africa and Canada. These are historical company-reported figures.
Veterinary translation · OxyglobinThe document records FDA approval in 1998 and European approval in 1999 for canine anemia, providing an early commercial veterinary example of a hemoglobin oxygen therapeutic.
Manufacturing platformBiopure described proprietary purification and polymerization processes, computerized process monitoring, Cambridge capacity expansion and plans for a larger South Carolina manufacturing facility.